1. Home
  2. RENE vs NVCT Comparison

RENE vs NVCT Comparison

Compare RENE & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RENE
  • NVCT
  • Stock Information
  • Founded
  • RENE 2021
  • NVCT 2020
  • Country
  • RENE United States
  • NVCT United States
  • Employees
  • RENE N/A
  • NVCT N/A
  • Industry
  • RENE Blank Checks
  • NVCT Medicinal Chemicals and Botanical Products
  • Sector
  • RENE Finance
  • NVCT Health Care
  • Exchange
  • RENE Nasdaq
  • NVCT Nasdaq
  • Market Cap
  • RENE 153.8M
  • NVCT 170.3M
  • IPO Year
  • RENE 2022
  • NVCT 2022
  • Fundamental
  • Price
  • RENE $11.92
  • NVCT $8.87
  • Analyst Decision
  • RENE
  • NVCT Strong Buy
  • Analyst Count
  • RENE 0
  • NVCT 3
  • Target Price
  • RENE N/A
  • NVCT $15.67
  • AVG Volume (30 Days)
  • RENE 96.5K
  • NVCT 128.2K
  • Earning Date
  • RENE 01-01-0001
  • NVCT 05-06-2025
  • Dividend Yield
  • RENE N/A
  • NVCT N/A
  • EPS Growth
  • RENE N/A
  • NVCT N/A
  • EPS
  • RENE 0.40
  • NVCT N/A
  • Revenue
  • RENE N/A
  • NVCT N/A
  • Revenue This Year
  • RENE N/A
  • NVCT N/A
  • Revenue Next Year
  • RENE N/A
  • NVCT N/A
  • P/E Ratio
  • RENE $29.52
  • NVCT N/A
  • Revenue Growth
  • RENE N/A
  • NVCT N/A
  • 52 Week Low
  • RENE $11.18
  • NVCT $4.44
  • 52 Week High
  • RENE $11.94
  • NVCT $11.80
  • Technical
  • Relative Strength Index (RSI)
  • RENE 67.55
  • NVCT 51.36
  • Support Level
  • RENE $11.83
  • NVCT $8.70
  • Resistance Level
  • RENE $11.93
  • NVCT $10.19
  • Average True Range (ATR)
  • RENE 0.01
  • NVCT 0.93
  • MACD
  • RENE 0.00
  • NVCT -0.08
  • Stochastic Oscillator
  • RENE 81.82
  • NVCT 40.45

About RENE Cartesian Growth Corporation II

Cartesian Growth Corp II is a blank check company.

About NVCT Nuvectis Pharma Inc.

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

Share on Social Networks: